# Oxybutynin and Omega-3 for OAB (Overactive Bladder)

> **NCT02070042** · NA · TERMINATED · sponsor: **TriHealth Inc.** · enrollment: 31 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **DRUG:** Omega 3 Fatty Acid
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02070042
- **Lead sponsor:** TriHealth Inc.
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-02
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Lack of participation
- **Last updated:** 2018-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02070042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02070042, "Oxybutynin and Omega-3 for OAB (Overactive Bladder)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02070042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*